- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00055926
CP-724,714 in Treating Patients With Metastatic Breast Cancer
A Phase I Safety and Pharmacokinetic/Pharmacodynamic Study of CP-724, 714 In Patients With Metastatic HER2-Overexpressing Breast Cancer
RATIONALE: CP-724,714 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.
PURPOSE: Phase I trial to study the effectiveness of CP-724,714 in treating patients who have metastatic HER2-overexpressing breast cancer.
Descripción general del estudio
Descripción detallada
OBJECTIVES:
- Determine the safety and tolerability of CP-724,714 in patients with metastatic HER2-overexpressing breast cancer.
- Determine the maximum tolerated dose of this drug in these patients.
- Determine, preliminarily, any antitumor activity of this drug in these patients.
- Determine the pharmacokinetics of this drug in these patients.
- Determine the relationship of drug-related adverse events to pharmacokinetic exposure parameters in these patients.
- Determine the relationship of changes in serum HER2 extracellular domain and HER2 receptor tyrosine kinase phosphorylation to pharmacokinetic exposure parameters and clinical outcome in patients treated with this drug.
OUTLINE: This is an open-label, dose-escalation, multicenter study.
Patients receive oral CP-724,714 on days 1 and 3-21 during course 1 and then daily during subsequent courses. Courses repeat every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of CP-724,714 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Patients are followed for at least 30 days.
PROJECTED ACCRUAL: A total of 3-20 patients will be accrued for this study within 6 months.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
California
-
Los Angeles, California, Estados Unidos, 90095-1781
- Jonsson Comprehensive Cancer Center, UCLA
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Histologically or cytologically confirmed HER2-overexpressing breast cancer
- Prior or newly documented HER2 amplification by fluorescence in situ hybridization (FISH)
- Progressive metastatic disease
- Must have received at least one prior chemotherapy regimen for metastatic breast cancer
- At least 1 measurable or evaluable lesion
- At least 1 lesion accessible for 2 separate core biopsies for pharmacodynamic evaluation
- 18 and over
- Male or female
- ECOG 0-1
- Life expectancy, More than 3 months
Hematopoietic
- Absolute neutrophil count at least 1,500/mm^3*
- Platelet count at least 100,000/mm^3* NOTE: *Without hematopoietic growth factors or transfusions
Hepatic
- Bilirubin no greater than 1.5 mg/dL
- AST/ALT no greater than 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases are present)
Renal
- Creatinine no greater than 1.5 times ULN OR
- Creatinine clearance at least 60 mL/min
Cardiovascular
- 12-lead ECG with normal tracing
- history of cardiovascular disease (i.e., ischemic heart disease, arrhythmia, or congestive heart failure) unless asymptomatic for the past year with no requirement for antiarrhythmics or a clinically significant medical management change
Gastrointestinal
- Able to take oral medication* Negative pregnancy test
- Fertile patients must use effective contraception
- At least 4 weeks since prior trastuzumab (Herceptin)
- At least 4 weeks since other prior biologic therapy or immunotherapy
- At least 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas)
- At least 6 months since prior doxorubicin or doxorubicin equivalents without any prior or developing signs or symptoms of cardiomyopathy
- No cumulative doses of more than 300 mg/m^2
- At least 2 weeks since prior hormonal therapy for the primary disease
- Concurrent hormone replacement therapy or luteinizing hormone-releasing hormone agonists allowed
- At least 4 weeks since prior radiotherapy
- At least 3 weeks since prior major surgery (2 weeks for minor surgery)
- Recovered from prior therapy
- At least 4 weeks since prior investigational treatment
- Coumarin or heparin derivatives allowed for the prevention of deep vein thrombosis or port patency
Exclusion Criteria:
- known or clinically suspected brain metastases or leptomeningeal disease
- symptomatic edema or third-space fluid (e.g., ascites or pleural effusions)
- known hepatitis B or C infection
- significant ECG changes that require medical intervention
- QTc interval less than 460 msec
- No history of torsade or other symptomatic QTc abnormality
- LVEF greater than 50% by MUGA
- gastrointestinal abnormality that would require medications (including all antacids)
- persistent symptoms of an esophageal or digestive disorder
- pregnant or nursing
- known HIV infection
- active infection
- concurrent uncontrolled systemic disorders or laboratory abnormalities that would preclude study drug safety evaluation
- mental disorder that would preclude study compliance or ability to give informed consent
- No more than 2 prior trastuzumab-based regimens for advanced disease
- concurrent immunotherapy
- more than 1 prior anthracycline- or anthracenedione-containing regimen (except with approval of the sponsor)
- prior high-dose chemotherapy with hematopoietic stem cell transplantation
- concurrent anticancer chemotherapy
- No concurrent anticancer hormonal therapy, including tamoxifen
- prior radiotherapy to the only disease site that would be assessed for response
- concurrent radiotherapy
- prior partial or complete gastrectomy
- concurrent antiarrhythmics
- concurrent antacids
- concurrent anticoagulant at therapeutic doses
- other concurrent experimental anticancer medications for breast cancer
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Enmascaramiento: Ninguno (etiqueta abierta)
Colaboradores e Investigadores
Patrocinador
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CDR0000271533
- UCLA-0209105
- PFIZER-A4031001
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer de mama
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University y otros colaboradoresTerminadoLa guía de aplicación clínica de Conebeam Breast CTPorcelana
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos
Ensayos clínicos sobre CP-724,714
-
Brigham and Women's HospitalReclutamiento
-
PfizerTerminadoObesidadEstados Unidos, Australia, Canadá, Brasil, Eslovaquia, República Checa, Argentina, Alemania, México, Reino Unido, Suecia
-
Siemens Molecular ImagingTerminadoCáncer de mamaEstados Unidos
-
PfizerTerminadoObesidadAustralia, Estados Unidos, Corea, república de, España, Francia, Reino Unido, Alemania, Suecia, Argentina, Chile, México
-
University of California, San FranciscoCalifornia Breast Cancer Research ProgramTerminado
-
Institute for Clinical and Experimental MedicineReclutamientoInfarto de miocardio | Choque Cardiogénico | Remodelación VentricularChequia
-
PfizerTerminadoFracturas TibialesEstados Unidos, Australia, Canadá, España, Pavo, Croacia, India, Bosnia y Herzegovina, Japón, Federación Rusa, Sudáfrica
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoTumores sólidos avanzadosEstados Unidos
-
Abramson Cancer Center of the University of PennsylvaniaTerminado
-
PfizerTerminadoSarcoma de EwingEstados Unidos, Reino Unido